TITLE

ANGINA PECTORIS

AUTHOR(S)
Shapiro, Shepard
PUB. DATE
February 1961
SOURCE
Angiology;Feb1961, Vol. 12 Issue 2, p53
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Angina pectoris occurs when the oxygen supply to the myocardium falls below the physiologic requirement of the moment. This anoxia is reversible and when the oxygen supply becomes adequate the angina attack subsides. These attacks can be prevented or controlled by coronary vasodilator drugs. The drug described in this study, isosorbide dinitrate, has been effective in about three-fourths of 51 patients with severe angina. Thirty-nine of the patients experienced either disappearance of the pain symptom or substantial reduction in frequency and duration of attacks. In view of the fact that the angina attacks were uniformly severe in this group of patients, in my opinion, the consistency and degree of response to isosorbide dinitrate therapy was satisfactory.
ACCESSION #
16395626

 

Related Articles

  • Medical Management of Angina Pectoris. Burch, G. E. // Angiology;Oct1979, Vol. 30 Issue 10, p667 

    Discusses the treatment or medical management of angina pectoris. Aspects of medical management for effective care of patients with angina pectoris; Need for the application of the existing knowledge to the best interest of patients suffering from various syndromes of ischemic heart disease;...

  • Drug Eluting Stents in Interventional Cardiology - Current Evidence and Emerging Uses. Swanson, N.; Gershlick, A. H. // Current Drug Targets - Cardiovascular & Haematological Disorders;Aug2005, Vol. 5 Issue 4, p313 

    Intervention in coronary artery disease is an area of cardiology where novel drugs, in the form of drug-eluting stents (DES), are being used increasingly commonly. DES are used across the whole range of coronary intervention, from stable angina patients with single or multivessel disease, acute...

  • Clinical Non-inferiority Trial on Treatment of Coronary Heart Disease Angina Pectoris of Xin-blood Stasis Syndrome Type with Lyophilized Salvia Salt of Lithospermic Acid Powder for Injection. Zhang Qiong; Liu Ai-Dong; Huang Yong-Sheng // Chinese Journal of Integrative Medicine;Mar2006, Vol. 12 Issue 1, p12 

    Objective: To evaluate the effectiveness and safety of lyophilized Salvia salt of lithospermic acid powder for injection (SSLA) in treating coronary heart diseases angina pectoris (CHD-AP) of Xin-blood stasis syndrome type, and to conduct the non-inferiority trial with Danshen injection (DSI) as...

  • Nicorandil in angina: a favourable economic impact.  // PharmacoEconomics & Outcomes News;7/15/2006, Issue 507, p1 

    Discusses research being done on the addition of nicorandil to usual angina pectoris treatment. Reference to a study by A. Walker et al, in the May 2006 issue of "Heart"; Benefits from the added nicorandil; Cost of nicorandil.

  • Modified-Release Formulation of Trimetazidine for Exceptional Control of Angina Pectoris: Fact or Fiction. Thadani, Udho // American Journal of Cardiovascular Drugs;2005, Vol. 5 Issue 5, p331 

    Discusses the truth behind the modified-release formulation of trimetazidine for exceptional control of angina pectoris. Description of angina pectoris; Cornerstone of therapy to reduce anginal symptoms and increase angina-free exercise capacity; Dosage of antianginal drugs that should be used.

  • Spinal Cord Stimulation Significantly Improves Refractory Angina Pectoris-A Local Experience: Spinal Cord Stimulation in Refractory Angina Chua, Roderick; Keogh, Anne // Heart, Lung & Circulation;Mar2005, Vol. 14 Issue 1, p3 

    Background:: Severe refractory angina pectoris can occur in end-stage coronary artery disease despite maximal medical and revascularization therapy. Spinal cord stimulation is an under-utilized but well-established modality for the treatment of intractable angina pain. Aim:: To illustrate the...

  • Keeping angina at bay.  // Cortlandt Forum;Jun2006, Vol. 19 Issue 6, p16 

    The article features Ranexa, an antianginal drug introduced by CV Therapeutics Inc. It is a medication for chronic angina that is inadequately controlled with other antianginals. It is used with amlodipine, beta blockers, or nitrates. It has antianginal and anti-ischemic effects that do not...

  • A LONG-TERM THERAPY OF ISCHEMIC HEART DISEASE. Griep, Arthur H. // Angiology;Sep1963, Vol. 14 Issue 9, p484 

    1. Fifty patients with angina pectoris caused by various forms of ischemic heart disease received long-term oral therapy with dipyridamole in doses of 25 mg. t.i.d. or q.i.d. 2. Results at the end of a 6-month period of therapy revealed: 80 per cent (40 patients) improved; 20 per cent (10...

  • Nicorandil: A Review of its Use in the Management of Stable Angina Pectoris, Including High-Risk Patients. Simpson, Dene; Wellington, Ken // Drugs;2004, Vol. 64 Issue 17, p1941 

    Nicorandil (Adancor®, Angicor®, Dancor®, Nikoril® [Europe], Ikorel® [Europe and Oceania], Sigmart® [Japan, Korea and Taiwan]) is an adenosine triphosphate (ATP)-sensitive potassium (KATP) channel agonist with nitrate-like properties used in the management of stable angina...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics